Platelet response
| Variable . | Total (n = 138) . | Statistical significance (P value) . |
|---|---|---|
| Quality of response | ||
| Patients with a platelet response, n (%) | 109 (79.0) | |
| Response stratified by variables | ||
| Age in y (<65 vs ≥65), % | 76.7 vs 80.5 | .584 |
| Sex (men vs women), % | 78.7 vs 79.2 | .939 |
| Baseline platelet count (<20 × 109/L vs ≥20 × 109/L), % | 80.2 vs 79.2 | .882 |
| Prior therapy with IVIG (yes/no), % | 73.8 vs 83.1 | .181 |
| Prior therapy with TPO-RAs (yes/no), % | 76.1 vs 80.3 | .326 |
| Prior therapy with rituximab (yes/no), % | 70.0 vs 82.6 | .098 |
| Splenectomized vs nonsplenectomized, % | 89.5 vs 77.3 | .227 |
| Bleeding at diagnosis (yes/no), % | 78.9 vs 77.5 | .653 |
| Charlson comorbidity index at diagnosis (0 vs ≥1), % | 75.0 vs 84.4 | .177 |
| Fostamatinib received in first/second line vs third line or later, % | 84.6 vs 78.4 | .601 |
| Fostamatinib use in primary ITP vs secondary ITP, % | 80.3 vs 68.7 | .413 |
| Fostamatinib monotherapy vs use in combination, % | 85.4 vs 69.6 | .026 |
| Platelet count at fostamatinib initiation (<20 × 109/L vs ≥20 × 109/L), % | 67.2 vs 88.7 | .002 |
| Fostamatinib use in chronic ITP vs nonchronic ITP, % | 79.2 vs 76.9 | .774 |
| Patients with a complete response, n (%) | 74 (53.6) | |
| Duration of response | ||
| Proportion of time with platelet response, % | 83.3 | |
| No. of patients with relapse after response, n (%) | 19 (13.8) | |
| Treatments after fostamatinib | ||
| Avatrombopag | 5 | |
| Romiplostim | 3 | |
| Steroids | 3 | |
| Steroids + immunosuppressants | 2 | |
| Immunoglobulins | 2 | |
| Eltrombopag | 1 | |
| Rituximab | 1 | |
| Cyclosporine | 1 | |
| Splenectomy | 1 | |
| Death | 9 |
| Variable . | Total (n = 138) . | Statistical significance (P value) . |
|---|---|---|
| Quality of response | ||
| Patients with a platelet response, n (%) | 109 (79.0) | |
| Response stratified by variables | ||
| Age in y (<65 vs ≥65), % | 76.7 vs 80.5 | .584 |
| Sex (men vs women), % | 78.7 vs 79.2 | .939 |
| Baseline platelet count (<20 × 109/L vs ≥20 × 109/L), % | 80.2 vs 79.2 | .882 |
| Prior therapy with IVIG (yes/no), % | 73.8 vs 83.1 | .181 |
| Prior therapy with TPO-RAs (yes/no), % | 76.1 vs 80.3 | .326 |
| Prior therapy with rituximab (yes/no), % | 70.0 vs 82.6 | .098 |
| Splenectomized vs nonsplenectomized, % | 89.5 vs 77.3 | .227 |
| Bleeding at diagnosis (yes/no), % | 78.9 vs 77.5 | .653 |
| Charlson comorbidity index at diagnosis (0 vs ≥1), % | 75.0 vs 84.4 | .177 |
| Fostamatinib received in first/second line vs third line or later, % | 84.6 vs 78.4 | .601 |
| Fostamatinib use in primary ITP vs secondary ITP, % | 80.3 vs 68.7 | .413 |
| Fostamatinib monotherapy vs use in combination, % | 85.4 vs 69.6 | .026 |
| Platelet count at fostamatinib initiation (<20 × 109/L vs ≥20 × 109/L), % | 67.2 vs 88.7 | .002 |
| Fostamatinib use in chronic ITP vs nonchronic ITP, % | 79.2 vs 76.9 | .774 |
| Patients with a complete response, n (%) | 74 (53.6) | |
| Duration of response | ||
| Proportion of time with platelet response, % | 83.3 | |
| No. of patients with relapse after response, n (%) | 19 (13.8) | |
| Treatments after fostamatinib | ||
| Avatrombopag | 5 | |
| Romiplostim | 3 | |
| Steroids | 3 | |
| Steroids + immunosuppressants | 2 | |
| Immunoglobulins | 2 | |
| Eltrombopag | 1 | |
| Rituximab | 1 | |
| Cyclosporine | 1 | |
| Splenectomy | 1 | |
| Death | 9 |
Platelet response and variables with statistically significant differences are indicated in bold. TPO-RAs, thrombopoietin receptor agonists.